Immediate Impact
72 standout
Citing Papers
PI3K/Akt/mTOR Signaling Pathway as a Target for Colorectal Cancer Treatment
2024 Standout
Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study
2024 Standout
Works of K. Azuma being referenced
A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study)
2015
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| K. Azuma | 77 | 50 | 3 | 39 | 7 | 114 | |
| Cheng Tzu Yen | 60 | 39 | 1 | 35 | 5 | 97 | |
| T. Y. Kim | 66 | 70 | 29 | 9 | 123 | ||
| Chengyou Du | 52 | 63 | 16 | 10 | 102 | ||
| Riccardo Memeo | 27 | 32 | 24 | 9 | 96 | ||
| Valentina Pomella | 34 | 91 | 25 | 7 | 97 | ||
| Nathalie Daaboul | 95 | 72 | 17 | 8 | 112 | ||
| Chebli Mrad | 63 | 56 | 2 | 33 | 8 | 101 | |
| Yei‐San Hsieh | 77 | 57 | 40 | 11 | 139 | ||
| Y. Humblet | 53 | 110 | 16 | 9 | 116 | ||
| Yi Ding | 36 | 46 | 1 | 26 | 9 | 116 |
All Works
Loading papers...